the prescription drug. (v) A list of government-granted exclusivities that prohibit the submission or approval of a prescription drug and the date that each such government-granted exclusivity was granted. (vi) The date on which the prescription drug was approved under such section 505 or such section 351 of the Public Health Service Act. (vii) The total expenditures of the manufacturer on— (I) domestic and foreign research and development, including an itemized description of— (aa) clinical research, including the cost of each clinical trial associated with the prescription drug, reported separately for each clinical trial